Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 2
1975 28
1976 40
1977 86
1978 75
1979 110
1980 113
1981 145
1982 181
1983 207
1984 195
1985 223
1986 243
1987 220
1988 287
1989 258
1990 292
1991 249
1992 230
1993 225
1994 184
1995 177
1996 157
1997 164
1998 188
1999 177
2000 186
2001 193
2002 215
2003 211
2004 207
2005 256
2006 253
2007 229
2008 219
2009 209
2010 206
2011 179
2012 215
2013 216
2014 228
2015 199
2016 183
2017 169
2018 156
2019 150
2020 168
2021 135
Text availability
Article attribute
Article type
Publication date

Search Results

8,413 results
Results by year
Filters applied: . Clear all
Page 1
Atenolol in hypertension: is it a wise choice?
Carlberg B, Samuelsson O, Lindholm LH. Carlberg B, et al. Lancet. 2004 Nov 6-12;364(9446):1684-9. doi: 10.1016/S0140-6736(04)17355-8. Lancet. 2004. PMID: 15530629
FINDINGS: We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with other antihypertensive drugs. ...Moreover, cardiovascular mortality also tended to be higher with atenolol treatment than with other …
FINDINGS: We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with …
Clinical pharmacokinetics of atenolol--a review.
Kirch W, Görg KG. Kirch W, et al. Eur J Drug Metab Pharmacokinet. 1982;7(2):81-91. doi: 10.1007/BF03188723. Eur J Drug Metab Pharmacokinet. 1982. PMID: 6749509 Review.
Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. ...Prolongation of elimination half life requires a dosage adjustment of atenolol in patients w
Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the aten
A Preliminary Investigation on the Effects of Atenolol for Treating Symptoms of Anxiety.
Armstrong C, Kapolowicz MR. Armstrong C, et al. Mil Med. 2020 Dec 30;185(11-12):e1954-e1960. doi: 10.1093/milmed/usaa170. Mil Med. 2020. PMID: 32728694
Primary measures collected were the rates of patient-reported (1) general beneficial/positive effect of atenolol, (2) adverse effects from atenolol, and (3) preference of atenolol to propranolol. ...Additionally, 100% of patients who had previously taken prop …
Primary measures collected were the rates of patient-reported (1) general beneficial/positive effect of atenolol, (2) adverse effects …
Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
Wadworth AN, Murdoch D, Brogden RN. Wadworth AN, et al. Drugs. 1991 Sep;42(3):468-510. doi: 10.2165/00003495-199142030-00007. Drugs. 1991. PMID: 1720383 Review.
Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administration of atenolol. ...There is also encouraging evidence of reduced mortality from cardiovascular disease during long term therapy with …
Oral atenolol is used for preventing recurrence of supraventricular arrhythmias once control is achieved by intravenous administratio …
A meta-analytical comparison of atenolol with angiotensin-converting enzyme inhibitors on arterial stiffness, peripheral blood pressure and heart rate in hypertensive patients.
Xie H, Luo G, Zheng Y, Peng F, Xie L. Xie H, et al. Clin Exp Hypertens. 2017;39(5):421-426. doi: 10.1080/10641963.2016.1267188. Epub 2017 May 23. Clin Exp Hypertens. 2017. PMID: 28534649 Review.
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral systolic blood pressure (PSBP) (WMD = -1.281 mmHg, 95% CI: -6.936 to 4.375, P = 0.657) did not differ significantly between atenolol
Overall changes in PWV (weighted mean difference or WMD = 0.068, 95% confidence interval or CI: -0.487 to -0.623, P = 0.811) and peripheral …
Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.
Heel RC, Brogden RN, Speight TM, Avery GS. Heel RC, et al. Drugs. 1979 Jun;17(6):425-60. doi: 10.2165/00003495-197917060-00001. Drugs. 1979. PMID: 38096 Review.
Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. ...There is no need for modification of dosage of atenolol in liver disease....
Atenolol is a beta-selective (cardioselective) adrenoceptor blocking drug without partial agonist or membrane stabilising activity. .
Atenolol and ischaemic heart disease: an overview.
Cruickshank JM, McAinsh J. Cruickshank JM, et al. Curr Med Res Opin. 1991;12(8):485-96. doi: 10.1185/03007999109111659. Curr Med Res Opin. 1991. PMID: 1764953 Review.
Data generated to date on the use of beta-blockers, especially atenolol, in ischaemic heart disease are reviewed and compared with the results available with the calcium antagonists. ...Atenolol, to date, is the only beta-blocker which has been demonstrated to have …
Data generated to date on the use of beta-blockers, especially atenolol, in ischaemic heart disease are reviewed and compared with th …
Bioavailability of atenolol formulations.
Mcainsh J, Simpson WT, Holmes BF, Young J, Ellis SH. Mcainsh J, et al. Biopharm Drug Dispos. 1980 Oct-Dec;1(6):323-32. doi: 10.1002/bdd.2510010604. Biopharm Drug Dispos. 1980. PMID: 7459427 Clinical Trial.
In this comparative bioavailability study two tablet formulations of atenolol (sales and clinical trial) were compared with an oral solution. Twelve healthy adult male volunteers received, on a cross-over basis, on three separate occasions, 100 mg oral dose of the three fo …
In this comparative bioavailability study two tablet formulations of atenolol (sales and clinical trial) were compared with an oral s …
The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats.
Han P, Shen FM, Xie HH, Chen YY, Miao CY, Mehta JL, Sassard J, Su DF. Han P, et al. J Cell Mol Med. 2009 Apr;13(4):726-34. doi: 10.1111/j.1582-4934.2008.00365.x. Epub 2009 Feb 12. J Cell Mol Med. 2009. PMID: 19220584 Free PMC article.
These animal models have different sensitivities to atenolol and amlodipine. The dosages of therapy employed were 10 mg/kg atenolol alone, 1 mg/kg amlodipine, 10 mg atenolol + 1 mg/kg amlodipine and 5 mg/kg atenolol+0.5 mg/kg amlodipine. ...After deter …
These animal models have different sensitivities to atenolol and amlodipine. The dosages of therapy employed were 10 mg/kg atenolo
Spectrofluorimetric method for atenolol determination based on gold nanoparticles.
Bakir E, Gouda M, Alnajjar A, Boraie WE. Bakir E, et al. Acta Pharm. 2018 Jun 1;68(2):243-250. doi: 10.2478/acph-2018-0020. Acta Pharm. 2018. PMID: 29702480 Free article.
A simple and sensitive spectrofluorimetric method for determination of atenolol (ATE) using gold nanoparticles (AuNPs) was developed. The method is based on the quenching effect of atenolol on photoluminescence of AuNPs at lambdaem = 705 nm. ...The proposed method w …
A simple and sensitive spectrofluorimetric method for determination of atenolol (ATE) using gold nanoparticles (AuNPs) was developed. …
8,413 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page